The trial is a prospective, single-arm, multi-center study, which will initially enroll 154 patients.

In the trial, the investigators will examine the safety and effectiveness of the CorPath 200 System in delivering and manipulating coronary guidewires and stent/balloon systems in percutaneous coronary intervention (PCI) procedures.

The CorPath 200 System is the medical device that offers interventional cardiologists complete PCI procedure control from an interventional cockpit.

The CorPath open-platform technology and intellectual property will enable Corindus to address other segments of the vascular market, including peripheral, neuro and structural heart applications.

CorPath PRECISE trial principal investigator Jeffrey Moses said the CorPath System’s radiation shielded cockpit provided an optimal view of the angiography screen had allowed to easily manipulate the guidewire and accurately place the stent.